Imugene to present cancer vaccine programs to the American Association for Cancer Research
Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced Dr Tanios Bekaii-Saab from the Mayo Clinic will present on its KEYVaxx and B-Vaxx cancer vaccine programs at the American Association for Cancer Research (AACR) 2019 Annual Meeting.
IMU is developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. It seeks to harness the body’s immune system to generate antibodies against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody therapies.
IMU’s product pipeline includes multiple immunotherapy B-cell vaccine candidates aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies.
IMU’s KEY-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours such as lung cancer by interfering with PD-1/PD-L1 binding and interaction, and produce an anti-cancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies that are transforming treatment of a range of cancers.
When combined with B-Vaxx, KEY-Vaxx, has shown great potential in preclinical studies, showing robust PD-1 and HER-2 antibody responses in all vaccinated mice. This indicates that the combined vaccination is effective in reducing tumour growth in a Balb/c syngeneic model of colon carcinoma versus either the PD-1 vaccine alone or more importantly the positive control gold standard that is anti-mouse PD-1 monoclonal antibody.
The presentations to the AACR Annual Meeting, scheduled for March 29 to April 3, 2019, will be presented by Dr Saab, the co-inventor of the KEY-Vaxx and B-Vaxx cancer vaccines with Professor Pravin Kaumaya, and member of the company’s Scientific Advisory Board.
The abstract presentations are titled:
- ‘Development of a novel PD-1 vaccine and in combination with two Chimeric HER-2 peptide vaccine provides synergistic inhibition of tumour growth in a syngeneic Balb/c model challenged with CT26/HER-2 carcinoma cell line’
- ‘A Phase I Active Immunotherapy Trial With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like) Human Epidermal Growth Factor Receptor 2 (HER-2) B Cell Peptide Vaccine Emulsified in ISA 720 and Nor-MDP Adjuvant in Patients With Advanced Solid Tumors’
The abstracts were authored by Dr Saab from the Mayo Clinic Cancer Center in Phoenix, AZ and researchers, including Prof. Kaumaya at the Ohio State University, Columbus, OH, UCLA, Los Angeles, CA and Emory University, Atlanta, GA.
The Phase I B-Vaxx trial studied the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumours. Vaccines made from antibodies and peptides may help the body build an effective immune response to kill tumour cells.
The open-label, dose escalation study evaluated B-Vaxx in patients with solid tumours that over express the HER-2/neu receptor. B-Vaxx has been shown to stimulate a potent polyclonal antibody response to HER-2/nue, a well established and validated cancer target.
B-Vaxx is a proprietary B-cell peptide cancer vaccine being developed by Imugene and targeting multiple oncology indications. A Phase 2 study evaluating the activity of B-Vaxx in patients over expressing HER-2/nue is being conducted at renowned clinical institutions in the US.
The abstract describes data from preclinical studies and a Phase I study conducted by the research team at Ohio State University Comprehensive Cancer Centre led by Professor Kaumaya with BVaxx for the treatment of solid tumours.
The content of the presentations will be made available at the start of the conference and will be made available online after the start of the meeting. An additional abstract detailing research from Imugene’s PD-1 Mimotope (Medical University of Vienna) program has also been accepted for poster presentation.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.